Abstract
Background Classification of nephrotic syndrome relies on clinical presentation and descriptive patterns of injury on kidney biopsies. This approach does not reflect underlying disease biology, limiting the ability to predict progression or treatment response.
Methods Systems biology approaches were used to categorize patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) based on kidney biopsy tissue transcriptomics across three cohorts and assessed association with clinical outcomes. Patient-level tissue pathway activation scores were generated using differential gene expression. Then, functional enrichment and non-invasive urine biomarker candidates were identified. Biomarkers were validated in kidney organoid models and single nucleus RNA-seq (snRNAseq) from kidney biopsies.
Results Transcriptome-based categorization identified three subgroups of patients with shared molecular signatures across independent North American, European and African cohorts. One subgroup demonstrated worse longterm outcomes (HR 5.2, p = 0.001) which persisted after adjusting for diagnosis and clinical measures (HR 3.8, p = 0.035) at time of biopsy. This subgroup’s molecular profile was largely (48%) driven by tissue necrosis factor (TNF) activation and could be predicted based on levels of TNF pathway urinary biomarkers TIMP-1 and MCP-1 and clinical features (correlation 0.63, p <0.001 for predicted vs observed score). Kidney organoids confirmed TNF-dependent increase in transcript and protein levels of these markers in kidney cells, as did snRNAseq from NEPTUNE biopsy samples.
Conclusions Molecular profiling identified a patient subgroup within nephrotic syndrome with poor outcome and kidney TNF pathway activation. Clinical trials using non-invasive biomarkers of pathway activation to target therapies are currently being evaluated.
Significance Statement Mechanistic, targeted therapies are urgently needed for patients with nephrotic syndrome. The inability to target an individual’s specific disease mechanism using currently used diagnostic parameters leads to potential treatment failure and toxicity risk. Patients with focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) were grouped by kidney tissue transcriptional profiles and a subgroup associated with poor outcomes defined. The segregation of the poor outcome group was driven by tumor necrosis factor (TNF) pathway activation and could be identified by urine biomarkers, MCP1 and TIMP1. Based on these findings, clinical trials utilizing non-invasive biomarkers of pathway activation to target therapies, improve response rates and facilitate personalized treatment in nephrotic syndrome have been initiated.
Competing Interest Statement
Dr. M. Kretzler reports grants from JDRF, Astra-Zeneca, NovoNordisc, Eli Lilly, Gilead, Goldfinch Bio, Janssen, Boehringer-Ingelheim, Moderna, European Union Innovative Medicine Innitiative, Chan Zuckerberg Initiative, Certa, Chinook, amfAR, Angion Pharmaceuticals, RenalytixAI, Travere Therapeutics, Regeneron, IONIS Pharmaceuticals, Astellas, Poxel, outside the submitted work. In addition, Dr. Kretzler has a patent PCT/EP2014/073413, Biomarkers and methods for progression prediction for chronic kidney disease, licensed. Also, outside of submitted work, Dr. L. Mariani has served on the advisory board of Reata Pharmaceuticals, Calliditas Therapeutics and Travere Therapeutics; Dr. H. Trachman is a member of the Kidney Health Initiative Executive Board and is involved in a consultancy agreement through NYU with Travere Therapeutics and Golfinch Bio, consultant to Chemocentryx (DMC) and Otsuka (Chair, DMC for pediatric trials); Dr. K.L. Gibson serves on Reata CKD Advisory Board and the Travere Inc. FSGS & IgA Advisory WorkGroup; Dr. V.K. Derebail reports funding from Novartis and has served on the advisory board of Retrophin and Bayer. All other authors have no disclosures to report.
Funding Statement
National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN) grant U54-DK-083912; additional funding and/or programmatic support by the Else Kroner-Fresenius Foundation (ERCB), University of Michigan, the NephCure Kidney International and the Halpin Foundation; NIH grant 2P30-DK-08194; grants from NIH/NHGRI/NIDDK: H3Africa Kidney Disease Study (U54 HG006939), H3Africa Kidney Disease Cohort Study (U01 DK107131), H3Africa Kidney Disease Collaborative Centers (9U54 DK116913). Dr Mariani is supported through funding from NIH/NIDDK, K08 DK115891-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For all cohorts, consent was obtained from individual patients or parents/guardians at enrollment, and the studies were approved by Institutional Review Boards or local ethics committees of participating institutions. NEPTUNE was approved (HUM00158219) by University of Michigan, Medical School Institutional Review Board. The ERCB ethics committee approval from the Ethikkommission bei der LMU Munchen, Ludwig-Maximilian-Universitat Munchen, Pettenkoferstr. 8a, 80336 Munchen, Ethical approval under 250-16. The H3 Africa study, STUDY00144768, was approved by University of Kansas Medical Center Institutional Review Board and ethics committees at each clinical site: Lagos University Teaching Hospital Health Research Ethics Committee (ADM/DCST/HREC/APP/1550); Aminu Kano Teaching Hospital (AKTH / MAC / SUB / 12A / P-3 / VI / 2032); Lagos State University Teaching Hospital (REF NO: LREC. 06/10/933); University Of Abuja Teaching Hospital (REF NO: FCT/UATH/HREC/PR/554); Ghana Health Service Ethics Review Committee (GHSERC: 014/07/19); Delta State University Teaching Hospital Health Research Ethics Committee (DELSUTH/HREC/2016/050/0198); Usmanu Danfodiyo University Teaching Hospital Health Research Ethics Committee (UDUTH / HREC / 2017 / 594); Nnamdi Azikiwe University Teaching Hospital (NAUTH/CS/66/VOL.12/ 058/2019/039); Kwame Nkrumah University of Science and Technology College Of Health Sciences Committee on Human Research, Publication and Ethics (Ref: CHRPE/ AP /335/20); Obafemi Awolowo University Teaching Hospital (ERC/2017 /06/16); University of Ibadan, College of Medicine (UI/EC/16/0399); University Of Nigeria Teaching Hospital (UNTH/CSA/329/VOL.5/010); University Of Ilorin Teaching Hospital (UITH ERC Protocol number: ERC PIN/2017/01/0511, UITH ERC Approval number: ERC PAN/2020/12/0107).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Transcriptional profiles of biopsies from patients with MCD and FSGS in the ERCB have been deposited to GEO and are part of accession numbers GSE104954 (tubulointerstitium) and GSE104948 (glomeruli).
